08/30/2017
NCCN has published updates to the NCCN GuidelinesĀ® and the NCCN CompendiumĀ® for Acute Lymphoblastic Leukemia
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs and Biologics Compendium (NCCN Compendium®) for Acute Lymphoblastic Leukemia. These NCCN Guidelines® are currently available as Version 2.2017.
- Relapsed/Refractory Disease (ALL-9)
- Ph-positive ALL
- Inotuzumab ozogamicin (category 2A) added as a treatment option for patients intolerant to TKIs or with disease refractory to TKIs.
- Ph-negative ALL
- Inotuzumab ozogamicin (category 1) added as a treatment option.
- Regimens for Relapsed/Refractory ALL (ALL-D 3 of 5)
- Footnote "j" added: Inotuzumab ozogamicin is associated with hepatotoxicity, including fatal and life-threatening hepatic veno-occlusive disease, and increased risk of post-hematopoietic stem cell transplant (HSCT) non-relapse mortality. For details, see: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf.
- Ph-positive ALL
- Inotuzumab ozogamicin (category 2A) added as a treatment option for patients intolerant to TKIs or with disease refractory to TKIs.
- Ph-negative ALL
- Inotuzumab ozogamicin (category 1) added as a treatment option.